Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension

P G KÜHL,* R B COTTON,† H SCHWEER,* AND H W SEYBERTH*

From the Departments of Paediatrics, *University of Heidelberg, West Germany, and †Vanderbilt University, Nashville, United States

SUMMARY Endogenous formation of thromboxane A₂ and prostacyclin were evaluated in seven neonates with persistent pulmonary hypertension by serial gas chromatographic mass spectrometric determination of their urinary metabolites dinor-thromboxane B₂ and dinor-6-keto-prostaglandin F₁₅, respectively. The patients were studied until their hypertension had resolved on clinical criteria. Urinary excretion of dinor-thromboxane B₂ and dinor-6-keto-prostaglandin F₁₅ was increased when the persistent pulmonary hypertension was associated with group B streptococcal (n=2) and pneumococcal (n=1) sepsis. Based on urinary metabolite excretion, endogenous formation of thromboxane A₂ and prostacyclin did not consistently differ from normal neonates in four patients with non-septic persistent pulmonary hypertension (hyaline membrane disease (n=2), asphyxia, and meconium aspiration). These data suggest that thromboxane A₂ is not a universal mediator of persistent pulmonary hypertension. It may, however, have a role in the pathophysiology of early onset group B streptococcal disease, and persistent pulmonary hypertension of other infectious aetiology. If these findings are confirmed by further studies, thromboxane synthetase inhibition or receptor antagonism may offer a potential therapeutic approach in neonates with persistent pulmonary hypertension associated with sepsis.

There is ample evidence in experimental animals to implicate the vasoconstrictor prostanoid thromboxane A₂ in the pathophysiology of acute pulmonary hypertension.¹⁻⁵ These conclusions are based on the effect of pharmacological intervention with cyclooxygenase¹ ² and thromboxane synthetase inhibitors,³ thromboxane receptor antagonists,⁴ and the measurements of thromboxane metabolites in plasma,² ³ ⁵ lung lymph,¹ and urine.⁵ Persistent pulmonary hypertension of the neonate is an example of increased pulmonary vascular resistance in the neonatal period and has lead to the hypothesis that thromboxane A₂ might be a modulator of pulmonary vascular tone in this condition. The aim of this study was to assess prostanoid biosynthesis in neonates with persistent pulmonary hypertension and healthy controls using urinary excretion rates of enzymatic metabolites of thromboxane A₂ (dionor-thromboxane B₂) and prostacyclin (dionor-6-keto-prostaglandin F₁₅) as indices of endogenous prostanoid formation.⁶

Patients and methods

Between April and June 1985 at Vanderbilt University Hospital and between March 1985 and January 1988 at the University Children’s Hospital, Heidelberg neonates who met the clinical criteria of persistent pulmonary hypertension were enrolled in the study on their first day of life. Patients were excluded from the study if they died early in the course of the disease so that an adequate urine collection could not be made.

Three infants born at full term and four preterm infants (two at Vanderbilt University Hospital, five at Children’s Hospital, Heidelberg) were available for study. Clinical suspicion of persistent pulmonary hypertension was based on severe labile hypoxaemia disproportionate to the severity of pulmonary disease and confirmed either by contrast echocardiography, hyperoxic hyperventilation test, or the difference between preductal and postductal arterial oxygen pressure (table).⁷ All patients were
mechanically ventilated with a maximum fractional inspiratory oxygen (FiO₂) value of 1.0 on day 1. 
FiO₂ requirements could be decreased to room air at a median of 13 (range 8–19) days. Mechanical ventilation was necessary for a median of 10 (range 5–19) days. Four of the infants were treated with tolazoline. One patient with meconium aspiration had an episode of thrombocytopenia, the lowest platelet count being 42×10⁹/l on day seven. None of the babies died.

Urine was collected for 12 to 24 hours on two to seven occasions during the first 12 days of life until the persistent pulmonary hypertension had clinically resolved. Collection was made in self adhesive bags or from an indwelling catheter, if clinically indicated, and urine volume was determined. Analysis of dinor-thromboxane B₂ and dinor-6-keto-prostaglandin F₁₅₂₀ by gas chromatography negative ion chemical ionisation mass spectrometry was carried out as described previously. Prostanoid metabolite excretion was expressed as ng/h/1·73 m². The normal range of prostanoid metabolite excretion during the neonatal period was determined on 56 occasions in 29 neonates some born preterm and some at full term, using the same methods.

The study protocol was approved by the ethics committees of both hospitals.

**Results**

Excretion of the thromboxane metabolite dinor-thromboxane B₂ varied considerably among the individual patients (fig 1). Whereas the neonates with persistent pulmonary hypertension associated with sepsis had excretion rates consistently above the normal range early in their course, the three other patients without sepsis (cases 4, 6, and 7 in the table) did not exceed control values. Case 5 (with severe perinatal asphyxia and meconium aspiration) had normal dinor-thromboxane B₂ excretion at the peak of the disease, which increased as the thrombocytopenia developed, and the FiO₂ went down to 0·5. Metabolite excretion reflected the clinical course—for example, the fraction of inspired oxygen as a global index of right to left shunting in cases 1 and 2. Case 3, however, was unique in that his dinor-thromboxane B₂ excretion peaked at a time when the pulmonary hypertension had resolved clinically and oxygen requirements had decreased to room air. For this reason, no further follow up data are available.

The association between FiO₂ requirements and the excretion rates of dinor-thromboxane B₂ is shown in fig 2. There was no positive correlation
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension

Again, patients with pulmonary hypertension associated with sepsis excreted more dinor-6-keto-prostaglandin F₁α than their non-septic counterparts.

Mean (SEM) urine output during the sampling periods was comparable in the two groups: 3-3 (0-3) ml/kg/h for patients with hypertension associated with sepsis and 3-2 (0-7) ml/kg/h for those without sepsis. Thus differences in urine output do not account for variations in metabolite excretion.

Discussion

The present study showed that urinary metabolite excretion was consistently higher early in the course of pulmonary hypertension associated with sepsis compared with hypertension without sepsis. The two groups of patients resembled each other in many respects—for example, the degree of ventilator dependency, oxygen requirements, and the number of central venous and arterial lines. The latter factor has been shown to increase excretion of both the thromboxane and prostacyclin metabolites.⁵ ⁹ The pattern of thromboxane and prostacyclin metabolite excretion, both in neonates with persistent pulmonary hypertension and normal neonates, agrees well with the results previously found in extremely low birthweight infants (less than 1000 g), although more immature and probably sicker premature infants tend to have higher excretion rates.⁸ Serial determinations of metabolite excretion did not mirror the clinical courses in non-septic patients with persistent pulmonary hypertension, whereas an association with FiO₂ requirements in pulmonary hypertension associated with sepsis is suggested. In the only patient with thrombocytopenia, thromboxane metabolite excretion reflected the decreasing platelet count rather than the course of pulmonary vasoconstriction, as shown by the oxygen dependency. Thus other factors—for example, platelet activation—have to be considered in the interpretation of increased thromboxane biosynthesis. Our results suggest that in persistent pulmonary hypertension, thromboxane A₂ is not apparently the only modulator of increased pulmonary vascular tone and that the relevance of thromboxane A₂ depends on the aetiology of the pulmonary hypertension. These data support the hypothesis that thromboxane A₂ may contribute to the pathophysiology of sepsis, as suggested by animal experiments.¹⁻⁵

On the other hand, these results of urinary thromboxane metabolite excretion are at variance with increased immunoreactive plasma thromboxane B₂ reported in persistent pulmonary hypertension or predominantly non-infectious aetiology by Hammerman et al.¹⁰ and Ford et al.¹¹ Circulating

Fig 2 Relationship between FiO₂ and excretion rates of dinor-thromboxane B₂ (logarithmic scale). Symbols for each patient are given in the table.

between these two variables in patients with persistent pulmonary hypertension not related to sepsis (r = -0.39 by linear regression analysis). In neonates in whom it was associated with sepsis, however, the two variables showed a trend towards positive correlation: linear regression analysis r = 0.33 (0.05 <p<0.1).

Excretion rates of the prostacyclin metabolite dinor-6-keto-prostaglandin F₁α followed the general pattern of the thromboxane metabolite (fig 3).

Fig 3 Urinary excretion of dinor-6-keto-prostaglandin F₁α (logarithmic scale). Symbols for each patient identification are given in the table. Shaded area=normal range.
plasma concentrations of thromboxane B2 have been estimated in the 1–2 pg/ml range in adults by infusion studies. Although plasma concentrations may be higher in neonates, plasma concentrations in the 30–3000 pg/ml or even 10–60 ng/ml range most likely reflect in vivo platelet activation rather than genuine circulating thromboxane B2 as an index of endogenous thromboxane A2 formation. Likewise the difference between normal controls and those with persistent pulmonary hypertension may mirror the fact that platelets in the latter may be more ‘sticky’ and easily activated, as shown by the incidence of thrombocytopenia in this study. The course of thromboxane metabolite excretion in our only thrombocytopenic patient is in agreement with this assumption. In the more standardised setting of an animal experiment, Hammerman et al were able to distinguish between pulmonary hypertension associated with sepsis and that associated with hypoxia on the basis of plasma thromboxane concentrations, which supports these data.

Any evaluation of endogenous thromboxane A2 and prostacyclin formation in clinical studies should rely on a dependable analytical approach. In this respect, thromboxane B2 and 6-ketoprostaglandin F1α in plasma are indices that may readily be confounded by in vivo artefacts. Urinary enzymatic metabolites have been shown to be useful analytical targets in various clinical studies. Our data obtained by such an approach show that endogenous thromboxane and prostacyclin formation are increased early in the course of persistent pulmonary hypertension associated with sepsis. If experience with more patients should confirm these results, new treatment modalities by thromboxane synthase inhibitors or receptor antagonists might improve the prognosis of certain subtypes of persistent pulmonary hypertension. In view of the increase in endogenous prostacyclin formation, however, exogenous administration of this potent pulmonary vasodilator does not seem to be a logical therapeutic intervention in persistent pulmonary hypertension associated with sepsis.

References


Correspondence to Dr P Gonne Kuhl, Universitats-Kinderklinik, Im Neuenheimer Feld 150, D-6900 Heidelberg. West Germany.

Accepted 15 February 1989
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.
P G Kühl, R B Cotton, H Schweer and H W Seyberth

Arch Dis Child 1989 64: 949-952
doi: 10.1136/adc.64.7_Spec_No.949

Updated information and services can be found at:
http://adc.bmj.com/content/64/7_Spec_No/949

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/